Cargando…

Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice

The current COVID-19 pandemic caused by constantly emerging SARS-CoV-2 variants still poses a threat to public health worldwide. Effective next-generation vaccines and optimized booster vaccination strategies are urgently needed. Here, we sequentially immunized mice with a SARS-CoV-2 wild-type inact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Shuo, Zhou, Bing, Cheng, Lin, Liu, Weilong, Fan, Qing, Ge, Xiangyang, Peng, Hua, Fu, Yang-Xin, Ju, Bin, Zhang, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724645/ https://www.ncbi.nlm.nih.gov/pubmed/34983583 http://dx.doi.org/10.1186/s12985-021-01737-3

Ejemplares similares

A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS‐CoV‐2 variants including BA.1 and BA.2 in vaccinated mice
por: Zhou, Bing, et al.
Publicado: (2022)

Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization
por: Guo, Huimin, et al.
Publicado: (2022)

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
por: Ma, Hang, et al.
Publicado: (2022)

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)

Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants
por: Lin, Wei-Shuo, et al.
Publicado: (2021)

Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes
por: Cheng, Lin, et al.
Publicado: (2021)

The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year
por: Zhang, Zheng, et al.
Publicado: (2022)

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
por: Yuan, Mengqi, et al.
Publicado: (2022)

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
por: Cheng, Lin, et al.
Publicado: (2021)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine
por: Ju, Bin, et al.
Publicado: (2022)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
por: Jia, Lina, et al.
Publicado: (2021)

Development of Receptor Binding Domain (RBD)‐Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS‐CoV‐2 Delta and Other Variants
por: Chen, Ran, et al.
Publicado: (2022)

Immunoglobulin fragment F(ab’)(2) against RBD potently neutralizes SARS-CoV-2 in vitro
por: Pan, Xiaoyan, et al.
Publicado: (2020)

Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
por: Liu, Yubin, et al.
Publicado: (2023)

A broad and potent neutralization epitope in SARS-related coronaviruses
por: Yuan, Meng, et al.
Publicado: (2022)

A broad and potent neutralization epitope in SARS-related coronaviruses
por: Yuan, Meng, et al.
Publicado: (2022)

An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines
por: Liu, Fei, et al.
Publicado: (2022)

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
por: Yuan, Mengqi, et al.
Publicado: (2023)

Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209
por: Ju, Bin, et al.
Publicado: (2022)

SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
por: Liu, Zheng, et al.
Publicado: (2022)

Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines
por: Dickey, Thayne H., et al.
Publicado: (2023)

Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response
por: Lin, Ting-Wei, et al.
Publicado: (2022)

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants
por: Wang, Lingshu, et al.
Publicado: (2021)

Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron
por: Zhou, Bing, et al.
Publicado: (2022)

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7
por: Zhang, Yanfang, et al.
Publicado: (2023)

Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
por: Chen, Yuxin, et al.
Publicado: (2021)

Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants
por: Fan, Feng, et al.
Publicado: (2023)

Potent neutralization of SARS‐CoV‐2 including variants of concern by vaccines presenting the receptor‐binding domain multivalently from nanoscaffolds
por: Halfmann, Peter J., et al.
Publicado: (2021)

A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern
por: Yang, Jingyi, et al.
Publicado: (2022)

Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift
por: Song, Ge, et al.
Publicado: (2023)

Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants
por: Svilenov, Hristo L., et al.
Publicado: (2022)

Camel nanobodies broadly neutralize SARS-CoV-2 variants
por: Hong, Jessica, et al.
Publicado: (2021)

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
por: Shi, Juan, et al.
Publicado: (2022)

Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
por: Chen, Wei-Hung, et al.
Publicado: (2023)

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
por: Zhang, Jing, et al.
Publicado: (2022)

Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants
por: Xu, Hua, et al.
Publicado: (2021)

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
por: Deshpande, Ashlesha, et al.
Publicado: (2021)

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
por: Luo, Deyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5t3il24iada54hcvmpggr91c8k